BUZZ-ASX-listed Mesoblast hits 8-month high; Bell Potter upbeat on Ryoncil revenues** Shares of inflammatory disease drug maker Mesoblast MSB.AX rise as much as 5.1% to A$3.07, their highest level since February 10
** Bell Potter lifts FY26 revenue forecast 38% to A$108 mln ($71.28 mln) after drug Ryoncil's Sept quarter gross revenue of A$21.5 mln beat estimates
** Brokerage expects Ryoncil revenues to rise each quarter, sees Sept quarter net revenue at A$19.1 mln
** Expects positive 1H26 EBITDA and equity-based remuneration, operating cash surplus likely by 4Q26
** Stock down 3.2% YTD, including the session's moves
($1 = 1.5152 Australian dollars)
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.